DAFNA Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,511,374	Closed	-$1.13M	–	78
2025 Q1	$1.13M	Hold	2,511,374	–	–	0.32%	52
2024 Q4	$1.26M	Buy	2,511,374 +1,160,666	+86%	+$852K	0.32%	53
2024 Q3	$1.22M	Hold	1,350,708	–	–	0.29%	58
2024 Q2	$1.35M	Sell	1,350,708 -15,600	-1%	-$17.2K	0.32%	54
2024 Q1	$2.02M	Buy	+1,366,308	New	+$1.55M	0.46%	45
2023 Q3	–	Sell	-140,000	Closed	-$197K	–	76
2023 Q2	$197K	Hold	140,000	–	–	0.05%	71
2023 Q1	$210K	Hold	140,000	–	–	0.06%	68
2022 Q4	$164K	Hold	140,000	–	–	0.05%	76
2022 Q3	$158K	Hold	140,000	–	–	0.04%	84
2022 Q2	$221K	Hold	140,000	–	–	0.06%	86
2022 Q1	$216K	Buy	140,000 +60,000	+75%	+$93.1K	0.06%	90
2021 Q4	$196K	Buy	+80,000	New	+$187K	0.05%	87
2021 Q2	–	Sell	-75,400	Closed	-$177K	–	89
2021 Q1	$177K	Sell	75,400 -4,600	-6%	-$11K	0.04%	87
2020 Q4	$141K	Sell	80,000 -15,000	-16%	-$21K	0.04%	74
2020 Q3	$89K	Hold	95,000	–	–	0.03%	79
2020 Q2	$83K	Hold	95,000	–	–	0.02%	86
2020 Q1	$79K	Hold	95,000	–	–	0.03%	79
2019 Q4	$85K	Hold	95,000	–	–	0.03%	80
2019 Q3	$93K	Hold	95,000	–	–	0.04%	86
2019 Q2	$105K	Hold	95,000	–	–	0.04%	82
2019 Q1	$124K	Sell	95,000 -5,000	-5%	-$6.22K	0.05%	76
2018 Q4	$91K	Sell	100,000 -14,300	-13%	-$21.9K	0.05%	79
2018 Q3	$235K	Sell	114,300 -93,269	-45%	-$196K	0.1%	71
2018 Q2	$374K	Hold	207,569	–	–	0.18%	64
2018 Q1	$489K	Sell	207,569 -106,756	-34%	-$250K	0.24%	60
2017 Q4	$591K	Buy	+314,325	New	+$686K	0.32%	58

Other funds holding LCTX